POET-II Trial Shortens Endocarditis Antibiotic Treatment

News-Medical · health

The POET-II trial has demonstrated that a response-tailored strategy can safely reduce antibiotic duration by two weeks for patients with left-sided infective endocarditis. This significant finding, presented at ESC Co..., suggests a potential shift in treatment protocols. Shortening treatment could lead to fewer side effects, reduced healthcare costs, and better patient outcomes by minimizing prolonged exposure to antibiotics.